RUNX1T1 and acute myeloid leukemia: Moreover, both siRNAs depleted RUNX1/ETO to similar extent in primary AML blasts showing that the site-directed introduction of modifications does not impair knockdown efficacy in patient-derived cells (Fig. 1h).